MedTrace Logo

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

NCT07762027 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-13

No results posted yet for this study

Summary

This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.

Conditions

  • Chronic Hepatitis D Infection

Interventions

DRUG

ABI-6250

Once daily tablet dosing for 48 weeks starting at Day 1 visit

DRUG

ABI-6250

Once daily tablet dosing for 48 weeks, starting at Week 16 visit

Sponsors & Collaborators

  • Assembly Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-06-30
Completion
2028-09-30

Countries

  • France
  • Georgia
  • Germany
  • Italy
  • Moldova
  • New Zealand
  • Pakistan
  • Romania
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07762027 on ClinicalTrials.gov